Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's ...

Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

An AstraZeneca and Daiichi Sankyo drug designed to replace chemotherapy was cleared by US regulators for broader use in late-stage breast cancer patients. The Food and Drug Administration ...

Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the USA as the first HER2-directed ...

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price ...

Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive ...

TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO ...